- Home
- TLPH vs SERA Comparison
TLPH vs SERA Comparison
Compare TLPH & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TLPH | SERA |
|---|---|---|
| Founded | 2005 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precision Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.3M | 75.2M |
| IPO Year | 2010 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TLPH | SERA |
|---|---|---|
| Price | $1.19 | $2.10 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 299.9K | 32.7K |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.32 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,151,000.00 | $81,000.00 |
| Revenue This Year | N/A | $554.81 |
| Revenue Next Year | N/A | $517.27 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 5.19 |
| 52 Week Low | $0.47 | $1.56 |
| 52 Week High | $1.57 | $3.95 |
Technical Indicators
Market Signals| Indicator | TLPH | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 42.96 | 52.62 |
| Support Level | $0.74 | $1.85 |
| Resistance Level | $1.48 | $2.12 |
| Average True Range (ATR) | 0.09 | 0.14 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 21.79 | 56.97 |
Price Performance
Historical ComparisonAbout TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It is a women's health company utilizing the proprietary proteomics and bioinformatics platform, and data resources to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.